| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.1 | 0.6 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.6 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | selumetinib:decitabine (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |